Your browser doesn't support javascript.
loading
An integrated in vitro carcinogenicity test that distinguishes between genotoxic carcinogens, non-genotoxic carcinogens, and non-carcinogens.
Chapman, Katherine E; Shah, Ume-Kulsoom; Fletcher, Jessica F; Johnson, George E; Doak, Shareen H; Jenkins, Gareth J S.
Afiliação
  • Chapman KE; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
  • Shah UK; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
  • Fletcher JF; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
  • Johnson GE; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
  • Doak SH; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
  • Jenkins GJS; Institute of Life Science, Swansea University Medical School, Swansea, SA2 8PP, United Kingdom.
Mutagenesis ; 39(2): 69-77, 2024 Mar 12.
Article em En | MEDLINE | ID: mdl-38301659
ABSTRACT
Chemical safety testing plays a crucial role in product and pharmacological development, as well as chemoprevention; however, in vitro genotoxicity safety tests do not always accurately predict the chemicals that will be in vivo carcinogens. If chemicals test positive in vitro for genotoxicity but negative in vivo, this can contribute to unnecessary testing in animals used to confirm erroneous in vitro positive results. Current in vitro tests typically evaluate only genotoxicity endpoints, which limits their potential to detect non-genotoxic carcinogens. The frequency of misleading in vitro positive results can be high, leading to a requirement for more informative in vitro tests. It is now recognized that multiple-endpoint genotoxicity testing may aid more accurate detection of carcinogens and non-carcinogens. The objective of this review was to evaluate the utility of our novel, multiple-endpoint in vitro test, which uses multiple cancer-relevant endpoints to predict carcinogenic potential. The tool assessed micronucleus frequency, p53 expression, p21 expression, mitochondrial respiration, cell cycle abnormalities and, uniquely, cell morphology changes in human lymphoblastoid cell lines, TK6 and MCL-5. The endpoints were used to observe cellular responses to 18 chemicals within the following categories genotoxic carcinogens, non-genotoxic carcinogens, toxic non-carcinogens, and misleading in vitro positive and negative agents. The number of endpoints significantly altered for each chemical was considered, alongside the holistic Integrated Signature of Carcinogenicity score, derived from the sum of fold changes for all endpoints. Following the calculation of an overall score from these measures, carcinogens exhibited greater potency than non-carcinogens. Genotoxic carcinogens were generally more potent than non-genotoxic carcinogens. This novel approach therefore demonstrated potential for correctly predicting whether chemicals with unknown mechanism may be considered carcinogens. Overall, while further validation is recommended, the test demonstrates potential for the identification of carcinogenic compounds. Adoption of the approach could enable reduced animal use in carcinogenicity testing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinógenos / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinógenos / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article